CRL · 10-Q · 2026Q2 · Full report
Headcount and Restructuring
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-08-05 · Importance 64 · Surprise 42 · Matches filing data
The company continues workforce right-sizing and site-optimization actions implemented over the past three years, including severance, transition costs, asset impairments, accelerated depreciation, and facility-consolidation charges. These initiatives, together with process improvements, procurement synergies, and a global business services model, are expected to generate approximately $300 million of cumulative annualized savings by the end of 2026. More than $175 million of the savings benefited fiscal 2025. Restructuring charges were $23.1 million in the second quarter and $54.6 million in the first half of 2026, compared with $99.8 million in fiscal 2025.
Key facts
- Restructuring charges incurred were $23.1 million and $54.6 million during the three and six months ended June 27, 2026, respectively. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | realized | -5.4% | Restructuring charges incurred were $23.1 million and $54.6 million during the three and six months ended June 27, 2026, respectively. |
| operating_income | negative | realized | -2.3% | Restructuring charges incurred were $23.1 million and $54.6 million during the three and six months ended June 27, 2026, respectively. |